Role of magnetic resonance imaging following postoperative radiotherapy in clinical decision-making of patients with high-grade glioma.
Neuroradiology
Pseudoprogression
Radiological assessment
Recurrent glioblastoma
Journal
La Radiologia medica
ISSN: 1826-6983
Titre abrégé: Radiol Med
Pays: Italy
ID NLM: 0177625
Informations de publication
Date de publication:
Jul 2022
Jul 2022
Historique:
received:
20
07
2021
accepted:
06
05
2022
pubmed:
25
5
2022
medline:
27
7
2022
entrez:
24
5
2022
Statut:
ppublish
Résumé
The present study aims to investigate the role of the first magnetic resonances (MRI) following radio-chemotherapy (RT-CT) in patients diagnosed with high-grade glioma. We retrospectively recorded radiological evaluations following RT-CT, symptoms related to disease progression (avoiding any sign due to radiotherapy or chemotherapy) and the change of therapeutic strategy. In March 2021, at data analysis, the data of 149 patients diagnosed with high-grade glioma and treated between May 2013 and July 2020 were retrieved for the present analysis. Two out of 122 (1.6%), 5 out of 106 (4.7%) and 8 out of 92 (8.6%) asymptomatic patients received the diagnosis of disease recurrence at the time of the first, second and third MRI, respectively. Otherwise, 16 out of 27 (59.2%), 16 out of 24 (66.6%) and 13 out of 16 (82.2%) symptomatic patients changed their therapy after the first, second and third MRI, respectively. Among patients that experienced radiological signs of distant progression, 10 out of 14 were symptomatic and changed their therapy. MRIs performed by 6 months after the end of RT-CT lead to change treatment strategy mostly in symptomatic patients.
Identifiants
pubmed: 35608757
doi: 10.1007/s11547-022-01502-8
pii: 10.1007/s11547-022-01502-8
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
803-808Informations de copyright
© 2022. Italian Society of Medical Radiology.
Références
Louis DN, Wesseling P, Aldape K, Brat DJ, Capper D, Cree IA, Eberhart C, Figarella-Branger D, Fouladi M, Fuller GN, Giannini C, Haberler C, Hawkins C, Komori T, Kros JM, Ng HK, Orr BA, Park SH, Paulus W, Perry A, Pietsch T, Reifenberger G, Rosenblum M, Rous B, Sahm F, Sarkar C, Solomon DA, Tabori U, van den Bent MJ, von Deimling A, Weller M, White VA, Ellison DW (2020) cIMPACT-NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and grading. Brain Pathol 30(4):844–856. https://doi.org/10.1111/bpa.12832
doi: 10.1111/bpa.12832
pubmed: 32307792
pmcid: 8018152
Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO, Groups EOfRaToCBTaR, Group NCIoCCT (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352 (10):987–996. https://doi.org/10.1056/NEJMoa043330
Wen PY, Weller M, Lee EQ, Alexander BM, Barnholtz-Sloan JS, Barthel FP, Batchelor TT, Bindra RS, Chang SM, Chiocca EA, Cloughesy TF, DeGroot JF, Galanis E, Gilbert MR, Hegi ME, Horbinski C, Huang RY, Lassman AB, Le Rhun E, Lim M, Mehta MP, Mellinghoff IK, Minniti G, Nathanson D, Platten M, Preusser M, Roth P, Sanson M, Schiff D, Short SC, Taphoorn MJB, Tonn JC, Tsang J, Verhaak RGW, von Deimling A, Wick W, Zadeh G, Reardon DA, Aldape KD, van den Bent MJ (2020) Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro Oncol 22(8):1073–1113. https://doi.org/10.1093/neuonc/noaa106
doi: 10.1093/neuonc/noaa106
pubmed: 32328653
pmcid: 7594557
Montemurro N, Anania Y, Cagnazzo F, Perrini P (2020) Survival outcomes in patients with recurrent glioblastoma treated with Laser Interstitial Thermal Therapy (LITT): A systematic review. Clin Neurol Neurosurg 195:105942. https://doi.org/10.1016/j.clineuro.2020.105942
doi: 10.1016/j.clineuro.2020.105942
pubmed: 32470780
Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, Degroot J, Wick W, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, Lamborn KR, Vogelbaum MA, van den Bent MJ, Chang SM (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28(11):1963–1972. https://doi.org/10.1200/JCO.2009.26.3541
doi: 10.1200/JCO.2009.26.3541
pubmed: 20231676
Montemurro N, Fanelli GN, Scatena C, Ortenzi V, Pasqualetti F, Mazzanti CM, Morganti R, Paiar F, Naccarato AG, Perrini P (2021) Surgical outcome and molecular pattern characterization of recurrent glioblastoma multiforme: A single-center retrospective series. Clin Neurol Neurosurg 207:106735. https://doi.org/10.1016/j.clineuro.2021.106735
doi: 10.1016/j.clineuro.2021.106735
pubmed: 34119900
Pasqualetti F, Montemurro N, Desideri I, Loi M, Giannini N, Gadducci G, Malfatti G, Cantarella M, Gonnelli A, Montrone S, Visani L, Scatena C, Naccarato AG, Perrini P, Gambacciani C, Santonocito O, Morganti R, Paiar F (2021) Impact of recurrence pattern in patients undergoing a second surgery for recurrent glioblastoma. Acta Neurol Belg. https://doi.org/10.1007/s13760-021-01765-4
doi: 10.1007/s13760-021-01765-4
pubmed: 34396487
Stupp R, Brada M, van den Bent MJ, Tonn JC, Pentheroudakis G, Group EGW (2014) High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 25(Suppl 3):iii93–iii101. https://doi.org/10.1093/annonc/mdu050
Sulman EP, Ismaila N, Chang SM (2017) Radiation therapy for glioblastoma: American society of clinical oncology clinical practice guideline endorsement of the American society for radiation oncology guideline. J Oncol Pract 13(2):123–127. https://doi.org/10.1200/JOP.2016.018937
doi: 10.1200/JOP.2016.018937
pubmed: 27907278
Booth TC, Luis A, Brazil L, Thompson G, Daniel RA, Shuaib H, Ashkan K, Pandey A (2021) Glioblastoma post-operative imaging in neuro-oncology: current UK practice (GIN CUP study). Eur Radiol 31(5):2933–2943. https://doi.org/10.1007/s00330-020-07387-3
doi: 10.1007/s00330-020-07387-3
pubmed: 33151394
Kruser TJ, Bosch WR, Badiyan SN, Bovi JA, Ghia AJ, Kim MM, Solanki AA, Sachdev S, Tsien C, Wang TJC, Mehta MP, McMullen KP (2019) NRG brain tumor specialists consensus guidelines for glioblastoma contouring. J Neurooncol 143(1):157–166. https://doi.org/10.1007/s11060-019-03152-9
doi: 10.1007/s11060-019-03152-9
pubmed: 30888558
pmcid: 6483830
von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, Initiative S (2007) The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med 147(8):573–577. https://doi.org/10.7326/0003-4819-147-8-200710160-00010
doi: 10.7326/0003-4819-147-8-200710160-00010
Perrini P, Gambacciani C, Weiss A, Pasqualetti F, Delishaj D, Paiar F, Morganti R, Vannozzi R, Lutzemberger L (2017) Survival outcomes following repeat surgery for recurrent glioblastoma: a single-center retrospective analysis. J Neurooncol 131(3):585–591. https://doi.org/10.1007/s11060-016-2330-7
doi: 10.1007/s11060-016-2330-7
pubmed: 27844310
Weller M, van den Bent M, Preusser M, Le Rhun E, Tonn JC, Minniti G, Bendszus M, Balana C, Chinot O, Dirven L, French P, Hegi ME, Jakola AS, Platten M, Roth P, Rudà R, Short S, Smits M, Taphoorn MJB, von Deimling A, Westphal M, Soffietti R, Reifenberger G, Wick W (2020) EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol. https://doi.org/10.1038/s41571-020-00447-z
doi: 10.1038/s41571-020-00447-z
pubmed: 33293629
pmcid: 7904519
Pasqualetti F, Gonnelli A, Molinari A, Cantarella M, Montrone S, Cristaudo A, Baldaccini D, Mattioni R, Delishaj D, Mazzotti V, Morganti R, Cocuzza P, Fabrini MG, Lombardi G, Rudà R, Soffietti R, Paiar F (2018) Different timing to use bevacizumab in patients with recurrent glioblastoma: early. Anticancer Res 38(10):5877–5881. https://doi.org/10.21873/anticanres.12930
doi: 10.21873/anticanres.12930
pubmed: 30275213
Macdonald DR, Cascino TL, Schold SC, Cairncross JG (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8(7):1277–1280. https://doi.org/10.1200/JCO.1990.8.7.1277
doi: 10.1200/JCO.1990.8.7.1277
pubmed: 2358840
Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S, Won M, Jeraj R, Brown PD, Jaeckle KA, Schiff D, Stieber VW, Brachman DG, Werner-Wasik M, Tremont-Lukats IW, Sulman EP, Aldape KD, Curran WJ, Mehta MP (2014) A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370(8):699–708. https://doi.org/10.1056/NEJMoa1308573
doi: 10.1056/NEJMoa1308573
pubmed: 24552317
pmcid: 4201043
Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Carpentier AF, Hoang-Xuan K, Kavan P, Cernea D, Brandes AA, Hilton M, Abrey L, Cloughesy T (2014) Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 370(8):709–722. https://doi.org/10.1056/NEJMoa1308345
doi: 10.1056/NEJMoa1308345
pubmed: 24552318
de Wit MC, de Bruin HG, Eijkenboom W, Sillevis Smitt PA, van den Bent MJ (2004) Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression. Neurology 63(3):535–537. https://doi.org/10.1212/01.wnl.0000133398.11870.9a
doi: 10.1212/01.wnl.0000133398.11870.9a
pubmed: 15304589
Brandsma D, Stalpers L, Taal W, Sminia P, van den Bent MJ (2008) Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 9(5):453–461. https://doi.org/10.1016/S1470-2045(08)70125-6
doi: 10.1016/S1470-2045(08)70125-6
pubmed: 18452856